Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6413549 | SALIX PHARMS | Fast-Dispersing solid oral dosage form containing coarse particles |
Jul, 2017
(6 years ago) |
Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 September, 2009
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7658914 | SALIX PHARMS | Colon cleansing compositions |
Sep, 2024
(4 months from now) | |
US7169381 | SALIX PHARMS | Colon cleansing compositions and methods |
Sep, 2024
(4 months from now) |
Market Authorisation Date: 02 August, 2006
Treatment: NA
Dosage: FOR SOLUTION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7687075 | SALIX PHARMS | Colonic purgative composition with soluble binding agent |
Jun, 2028
(4 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5616346 | SALIX PHARMS | Non-aqueous colonic purgative formulations |
May, 2013
(10 years ago) |
Market Authorisation Date: 16 March, 2006
Treatment: For cleansing the bowel in preparation for colonoscopy, in adults 18 years of age or older
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6559158 | SALIX PHARMS | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
Nov, 2017
(6 years ago) | |
US9669096 | SALIX PHARMS | Stable pharmaceutical formulations of methylnaltrexone |
Apr, 2024
(19 days ago) | |
US8552025 | SALIX PHARMS | Stable methylnaltrexone preparation |
Apr, 2024
(19 days ago) | |
US10376584 | SALIX PHARMS | Stable pharmaceutical formulations of methylnaltrexone |
Apr, 2024
(19 days ago) | |
US9492445 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(5 years from now) | |
US8822490 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(5 years from now) | |
US9180125 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(5 years from now) | |
US8420663 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(5 years from now) | |
US8247425 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Dec, 2030
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 24, 2013 |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
NCE-1 date: 24 April, 2012
Market Authorisation Date: 27 September, 2010
Treatment: Treatment of opioid-induced constipation
Dosage: SOLUTION;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5616346 | SALIX PHARMS | Non-aqueous colonic purgative formulations |
May, 2013
(10 years ago) |
Market Authorisation Date: 21 September, 2000
Treatment: Method of use of visicol
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8158781 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(a month from now) | |
US7902206 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(a month from now) | |
US7045620 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(a month from now) | |
US7612199 | SALIX PHARMS | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(a month from now) | |
US8835452 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(a month from now) | |
US7906542 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2025
(1 year, 1 month from now) | |
US8741904 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(1 year, 10 months from now) | |
US8193196 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Sep, 2027
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7605240 | SALIX PHARMS | Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth |
Aug, 2019
(4 years ago) | |
US7935799 | SALIX PHARMS | Methods of treating diarrhea caused by small intestinal bacterial overgrowth |
Aug, 2019
(4 years ago) | |
US7718608 | SALIX PHARMS | Methods of treating a subject suffering from irritable bowel syndrome |
Aug, 2019
(4 years ago) | |
US7452857 | SALIX PHARMS | Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Aug, 2019
(4 years ago) | |
US6861053 | SALIX PHARMS | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Aug, 2019
(4 years ago) | |
US8158644 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(a month from now) | |
US8853231 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(a month from now) | |
US7915275 | SALIX PHARMS | Use of polymorphic forms of rifaximin for medical preparations |
Feb, 2025
(9 months from now) | |
US10703763 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(1 year, 10 months from now) | |
US9271968 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(1 year, 10 months from now) | |
US8518949 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(1 year, 10 months from now) | |
US11564912 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(4 years from now) | |
US10456384 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(4 years from now) | |
US10765667 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(4 years from now) | |
US11779571 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(4 years from now) | |
US8309569 | SALIX PHARMS | Methods for treating diarrhea-associated irritable bowel syndrome |
Jul, 2029
(5 years from now) | |
US10709694 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(5 years from now) | |
US9421195 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(5 years from now) | |
US9629828 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(5 years from now) | |
US8829017 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(5 years from now) | |
US8946252 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(5 years from now) | |
US10335397 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(5 years from now) | |
US7928115 | SALIX PHARMS | Methods of treating travelers diarrhea and hepatic encephalopathy |
Jul, 2029
(5 years from now) | |
US10314828 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(5 years from now) | |
US8642573 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(5 years from now) | |
US8969398 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-709) | May 27, 2018 |
Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
New Product(NP) | Mar 24, 2013 |
Drugs and Companies using RIFAXIMIN ingredient
Market Authorisation Date: 24 March, 2010
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults.; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.; Reduction in risk of overt hepatic ...
Dosage: TABLET;ORAL